Insights
Search Results
Client Highlights
6.02.26
Firm Advises Noctrix on Acquisition by Resmed
On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.
Client Highlights
4.27.26
Wilson Sonsini Advises Nervonik on $52.5 Million Series B Financing
On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.
Client Highlights
2.26.26
Wilson Sonsini Advises QuiverAI on $8.3 Million Seed Financing
On February 25, 2026, QuiverAI, an AI lab and product company focused on vector design and visual code generation, announced it has completed an $8.3 million seed round. The financing was led by Andreessen Horowitz (a16z) with participation from K Fund, JME, Mission, and angel investors. Wilson Sonsini Goodrich & Rosati advised QuiverAI on the transaction.
Client Highlights
2.02.26
Wilson Sonsini Advises ALX Oncology on Public Offering
On January 30, 2026, ALX Oncology Holdings Inc., a clinical-stage biotechnology company focusing on novel therapies designed to treat cancer and extend patients’ lives, announced the pricing of an underwritten offering of 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offering. The gross proceeds of the offering are expected to be approximately $150 million before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the transaction.
Client Highlights
12.08.25
Firm Advises Check Point on $2 Billion Convertible Senior Notes Offering
On December 8, 2025, Check Point Software Technologies Ltd. completed an upsized offering of $2 billion aggregate principal amount of convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Check Point had granted to the initial purchasers to purchase up to an additional $250 million of notes. In connection with the offering, Check Point entered into privately negotiated capped call transactions with an affiliate of one of the initial purchasers and certain other financial institutions.
Client Highlights
9.17.25
Firm Advises Planet Labs on $460 Million Convertible Senior Notes Offering
On September 12, 2025, Planet Labs, PBC, completed an upsized offering of $460 million aggregate principal amount of convertible senior notes due 2030, in a private transaction. The offering amount included the exercise in full of the option that Planet Labs had granted to the initial purchasers to purchase up to an additional $60 million of notes. In connection with the offering, Planet Labs entered into privately negotiated capped call transactions with an affiliate of one of the initial purchasers and certain other financial institutions. Wilson Sonsini Goodrich & Rosati advised Planet Labs on the transaction.
Client Highlights
Wilson Sonsini Advises Replit on $250 Million Series C
On September 10, 2025, Replit, an agentic AI software creation platform, announced a $250 million Series C funding round led by Prysm Capital with participation from Amex Ventures and Google's AI Futures Fund as strategic investors. Existing investors, YC, Craft, a16z, Coatue, Paul Graham, and others increased their investments. Wilson Sonsini Goodrich & Rosati advised Replit on the transaction.